Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab plus rituximab in adults with systemic lupus erythematosus
NL-OMON50250Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Belimumab + rituximab with Belimumab + placebo (2 arms). Primary endpoint: Disease control at Week 52. Started May 2018; status: active, not recruiting.
02
Drugs
belimumabrituximab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON50250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50250.